Clinical trial

Intravenous Ketamine for Treatment-Resistant Depression

Mayo ClinicRecruitingPhase 2Started Feb 10, 202530 enrolledUnited StatesNCT06668571

Abstract

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

Major DepressionDepressive Disorder, Treatment-ResistantMDDTRDTreatment-Resistant DepressionTreatment-Resistant Major DepressionIntravenous KetamineDepressive Disorder, Treatment-ResistantTreatment Resistant Depression (TRD)

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.